Literature DB >> 9718175

Pure mucinous carcinoma of the breast: a clinicopathologic correlation study.

E Avisar1, M A Khan, D Axelrod, K Oza.   

Abstract

BACKGROUND: Pure mucinous carcinoma (PMC) of the breast has a better prognosis than does invasive ductal carcinoma not otherwise specified and is more prevalent in older patients. We investigated the correlation between prognostic indices and clinical outcome in this histologic subset.
METHODS: A retrospective review was done of patients with PMC treated between 1989 and 1996. Demographic data, pathologic indices of prognosis, axillary nodal status, and outcome were assessed.
RESULTS: Out of 6083 cases of breast carcinoma, 30 were PMC. Only 3 of 25 (12%) axillary dissections were positive. The average age of the group with positive nodes was 57 years, as compared to 69.5 years (95% CI; 63.24-75.76) in the group with negative nodes. All the tumors with positive nodes were aneuploid and had a high nuclear grade, compared to a 31.25% aneuploidy rate in the group without nodal disease (P = .058). Negative ER receptors were found in only 2 of 20 (10%) of the patients tested. Both had axillary disease (P = .016). Tumor size did not correlate with axillary metastasis. Two of the 29 patients died from unrelated diseases. The other 27 patients are alive with no evidence of disease.
CONCLUSIONS: Axillary nodal disease is rare in PMC and correlates with a younger age, aneuploidy, high nuclear grade, or a negative ER receptor status. Sentinel lymph node biopsy may help identify the need for axillary dissection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9718175     DOI: 10.1007/bf02303864

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.

Authors:  Qiuping Mo; Yongzhen Wang; JinLan Shan; Xiaochen Wang
Journal:  Radiat Oncol       Date:  2022-07-07       Impact factor: 4.309

2.  Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis.

Authors:  Soo Youn Bae; Min-Young Choi; Dong Hui Cho; Jeong Eon Lee; Seok Jin Nam; Jung-Hyun Yang
Journal:  J Breast Cancer       Date:  2011-12-27       Impact factor: 3.588

3.  Mucinous carcinoma with axillary lymph node metastasis in a male breast: A case report.

Authors:  Faten Hammedi; Amel Trabelsi; Soumaya Ben Abdelkrim; Lilia Ben Yacoub Abid; Wafa Jomaa; Ahlem Bdioui; Nadia Beizig; Moncef Mokni
Journal:  N Am J Med Sci       Date:  2010-02

4.  Magnetic resonance imaging and pathological characteristics of pure mucinous carcinoma in the breast according to echogenicity on ultrasonography.

Authors:  Young Gyung Shin; Eun-Kyung Kim; Min Jung Kim; Jung Hyun Yoon; Hee Jung Moon
Journal:  Ultrasonography       Date:  2016-08-29

5.  Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study.

Authors:  Hanwen Zhang; Ning Zhang; Yaming Li; Yiran Liang; Qifeng Yang
Journal:  Ther Adv Med Oncol       Date:  2020-12-18       Impact factor: 8.168

6.  Construction of a Prognostic Nomogram Model for Patients with Mucinous Breast Cancer.

Authors:  Xulong Zhu; Ying Li; Fende Liu; Feifei Zhang; Jianhui Li; Chong Cheng; Yanwei Shen; Nan Jiang; Jia Du; Yajing Zhou; Binliang Huo
Journal:  J Healthc Eng       Date:  2022-03-23       Impact factor: 2.682

7.  Breast-conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: A SEER population-based study.

Authors:  Ping Yu; Peng Liu; Yutian Zou; Xinhua Xie; Hailin Tang; Na Li; Xiaoming Xie; Feng Ye
Journal:  Cancer Med       Date:  2020-06-08       Impact factor: 4.452

8.  Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society.

Authors:  Hyung Suk Kim; Jong Uk Lee; Tae Kyung Yoo; Byung Joo Chae; Donghee Son; Yun Jin Kim; Woo Chan Park
Journal:  J Breast Cancer       Date:  2019-09-30       Impact factor: 3.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.